Eric Wooltorton
Abstract
Open-access reader
Reason for posting: Long-acting β2-agonist (LABA) medications are bronchodilators used in the treatment of asthma and chronic obstructive pulmonary disease. More than a decade ago questions were raised about an excess of asthma-related events, including death, in a study of salmeterol.[1][1]
OpenAlex reports 18 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Reason for posting: Long-acting β2-agonist (LABA) medications are bronchodilators used in the treatment of asthma and chronic obstructive pulmonary disease. More than a decade ago questions were raised about an excess of asthma-related events, including death, in a study of salmeterol.[1][1]
Key concepts: Salmeterol, Asthma, Medicine, Bronchodilator Agents, B2 receptor, Pulmonary disease, Agonist, Intensive care medicine